Dr. Wade J. Sexton, MD

Dr. Sexton practices at H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida.

Dr. Sexton's NPI, 1649286212, was assigned on August 1, 2006. Dr. Sexton graduated from Emory School of Medicine in 1993. Dr. Sexton holds Florida license ME91303.

Dr. Sexton's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD, at 10901 McKinley Dr, Tampa, FL 33612.

Dr. Sexton's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida. Dr. Sexton is also affiliated with Moffitt Cancer Hospital. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Sexton to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sexton practices, 4 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Sexton's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Sexton is board certified in urology by the American Board of Urology. Dmand AI has Dr. Sexton's licenses on file in 3 states: Florida, North Carolina and Texas.

Dmand AI lists bladder removal, enlarged prostate transurethral surgery (TURP), kidney removal surgery, kidney stones, prostate cancer, prostate surgery, transurethral procedures and urinary endoscopy among the conditions Dr. Sexton treats.

CMS data shows 332 Medicare services from Dr. Sexton across 8 procedure codes in 2024, for 228 Medicare patients. Medicare paid $40,812 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 228 Medicare patients who saw Dr. Sexton in 2024. The largest group is 75 to 84, with 107 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 2.01, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Sexton's median patient age at 74, with 27% women.

In 2024, Dr. Sexton wrote 122 Medicare Part D claims for 59 patients. 98% of them were for generic drugs. CMS names the drug for 76 of them, across 3 drugs with 11 or more claims each, at $608 in total drug cost. In 2023, CMS named 56 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Sexton for performance year 2024, reported as part of a group. Dr. Sexton accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Sexton as offering telehealth.

Prostate resection: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 180 papers to Dr. Sexton, published from 2003 to 2025. 2023 was the busiest year, with 13. The most frequent topics are Urinary Bladder Neoplasms, Kidney Neoplasms and Carcinoma, Transitional Cell. Dr. Sexton has published most often in J Urol. Dr. Sexton's most frequent co-authors are Philippe E. Spiess, MD, Scott Michael Gilbert, MD and Michael A. Poch, MD.

Dmand AI links Dr. Sexton to 4 clinical trials, 2 of them phase 1 studies. 1 is still active or recruiting. Conditions studied include Urinary Bladder Neoplasms, Urinary Bladder Diseases and Carcinoma, Transitional Cell. H. Lee Moffitt Cancer Center and Research Institute sponsors the most, 4.

CMS Open Payments shows 34 general payments to Dr. Sexton from 13 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 58% of the total. Urogen Pharma, Inc. paid the most, $4,397.

Dmand AI lists 15 awards for Dr. Sexton, most recently Moffitt Cancer Center Physician of the Year in 2019. Dr. Sexton serves on Moffitt Surgical Safety Committee and National Comprehensive Cancer Network (NCCN) for Bladder and Penile Cancers.

Dr. Sexton graduated from Emory School of Medicine in 1993. Dr. Sexton is a member of AUA.

Dr. Sexton is in network with 10 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. HMO plans come from the most carriers, 7. Check the plan with the practice before a visit.